Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort

G Fornarini; S E Rebuzzi; G L Banna; F Calabrò; G Scandurra; U De Giorgi; C Masini; C Baldessari; E Naglieri; C Caserta; S Manacorda; M Maruzzo; M Milella; C Buttigliero; R Tambaro; P Ermacora; F Morelli; F Nolè; C Astolfi; C N Sternberg

doi:10.1016/j.esmoop.2021.100118

Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort

G Fornarini, S E Rebuzzi, G L Banna, F Calabrò, G Scandurra, U De Giorgi, C Masini, C Baldessari, E Naglieri, C Caserta, S Manacorda, M Maruzzo, M Milella, C Buttigliero, R Tambaro, P Ermacora, F Morelli, F Nolè, C Astolfi, C N Sternberg

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: Reliable and affordable prognostic and predictive biomarkers for urothelial carcinoma treated with immunotherapy may allow patients' outcome stratification and drive therapeutic options. The SAUL trial investigated the safety and efficacy of atezolizumab in a real-world setting on 1004 patients with locally advanced or metastatic urothelial carcinoma who progressed to one to three prior systemic therapies.PATIENTS AND METHODS: Using the SAUL Italian cohort of 267 patients, we investigated the prognostic role of neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII) and the best performing one of these in combination with programmed death-ligand 1 (PD-L1) with or without lactate dehydrogenase (LDH). Previously reported cut-offs (NLR >3 and NLR >5; SII >1375) in addition to study-defined ones derived from receiver operating characteristic (ROC) analysis were used.RESULTS: The cut-off values for NLR and SII by the ROC analysis were 3.65 (sensitivity 60.4; specificity 63.0) and 884 (sensitivity 64.4; specificity 67.5), respectively. The median overall survival (OS) was 14.7 months for NLR

Original language	English
Article number	100118
Pages (from-to)	1-9
Number of pages	9
Journal	ESMO open
Volume	6
Issue number	3
DOIs	https://doi.org/10.1016/j.esmoop.2021.100118
Publication status	Published - May 10 2021

Access to Document

10.1016/j.esmoop.2021.100118

Cite this

Fornarini, G., Rebuzzi, S. E., Banna, G. L., Calabrò, F., Scandurra, G., De Giorgi, U., Masini, C., Baldessari, C., Naglieri, E., Caserta, C., Manacorda, S., Maruzzo, M., Milella, M., Buttigliero, C., Tambaro, R., Ermacora, P., Morelli, F., Nolè, F., Astolfi, C., & Sternberg, C. N. (2021). Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort. ESMO open, 6(3), 1-9. [100118]. https://doi.org/10.1016/j.esmoop.2021.100118

Fornarini, G, Rebuzzi, SE, Banna, GL , Calabrò, F, Scandurra, G, De Giorgi, U , Masini, C, Baldessari, C, Naglieri, E, Caserta, C, Manacorda, S, Maruzzo, M, Milella, M, Buttigliero, C, Tambaro, R, Ermacora, P, Morelli, F , Nolè, F, Astolfi, C & Sternberg, CN 2021, 'Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort', ESMO open, vol. 6, no. 3, 100118, pp. 1-9. https://doi.org/10.1016/j.esmoop.2021.100118

@article{b2c6b0aeeb934d0da5fef52ee178af3a,

title = "Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort",

abstract = "BACKGROUND: Reliable and affordable prognostic and predictive biomarkers for urothelial carcinoma treated with immunotherapy may allow patients' outcome stratification and drive therapeutic options. The SAUL trial investigated the safety and efficacy of atezolizumab in a real-world setting on 1004 patients with locally advanced or metastatic urothelial carcinoma who progressed to one to three prior systemic therapies.PATIENTS AND METHODS: Using the SAUL Italian cohort of 267 patients, we investigated the prognostic role of neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII) and the best performing one of these in combination with programmed death-ligand 1 (PD-L1) with or without lactate dehydrogenase (LDH). Previously reported cut-offs (NLR >3 and NLR >5; SII >1375) in addition to study-defined ones derived from receiver operating characteristic (ROC) analysis were used.RESULTS: The cut-off values for NLR and SII by the ROC analysis were 3.65 (sensitivity 60.4; specificity 63.0) and 884 (sensitivity 64.4; specificity 67.5), respectively. The median overall survival (OS) was 14.7 months for NLR ",

author = "G Fornarini and Rebuzzi, {S E} and Banna, {G L} and F Calabr{\`o} and G Scandurra and {De Giorgi}, U and C Masini and C Baldessari and E Naglieri and C Caserta and S Manacorda and M Maruzzo and M Milella and C Buttigliero and R Tambaro and P Ermacora and F Morelli and F Nol{\`e} and C Astolfi and Sternberg, {C N}",

year = "2021",

month = may,

day = "10",

doi = "10.1016/j.esmoop.2021.100118",

language = "English",

volume = "6",

pages = "1--9",

journal = "ESMO open",

issn = "2059-7029",

number = "3",

}

TY - JOUR

T1 - Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort

AU - Fornarini, G

AU - Rebuzzi, S E

AU - Banna, G L

AU - Calabrò, F

AU - Scandurra, G

AU - De Giorgi, U

AU - Masini, C

AU - Baldessari, C

AU - Naglieri, E

AU - Caserta, C

AU - Manacorda, S

AU - Maruzzo, M

AU - Milella, M

AU - Buttigliero, C

AU - Tambaro, R

AU - Ermacora, P

AU - Morelli, F

AU - Nolè, F

AU - Astolfi, C

AU - Sternberg, C N

PY - 2021/5/10

Y1 - 2021/5/10

N2 - BACKGROUND: Reliable and affordable prognostic and predictive biomarkers for urothelial carcinoma treated with immunotherapy may allow patients' outcome stratification and drive therapeutic options. The SAUL trial investigated the safety and efficacy of atezolizumab in a real-world setting on 1004 patients with locally advanced or metastatic urothelial carcinoma who progressed to one to three prior systemic therapies.PATIENTS AND METHODS: Using the SAUL Italian cohort of 267 patients, we investigated the prognostic role of neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII) and the best performing one of these in combination with programmed death-ligand 1 (PD-L1) with or without lactate dehydrogenase (LDH). Previously reported cut-offs (NLR >3 and NLR >5; SII >1375) in addition to study-defined ones derived from receiver operating characteristic (ROC) analysis were used.RESULTS: The cut-off values for NLR and SII by the ROC analysis were 3.65 (sensitivity 60.4; specificity 63.0) and 884 (sensitivity 64.4; specificity 67.5), respectively. The median overall survival (OS) was 14.7 months for NLR

AB - BACKGROUND: Reliable and affordable prognostic and predictive biomarkers for urothelial carcinoma treated with immunotherapy may allow patients' outcome stratification and drive therapeutic options. The SAUL trial investigated the safety and efficacy of atezolizumab in a real-world setting on 1004 patients with locally advanced or metastatic urothelial carcinoma who progressed to one to three prior systemic therapies.PATIENTS AND METHODS: Using the SAUL Italian cohort of 267 patients, we investigated the prognostic role of neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII) and the best performing one of these in combination with programmed death-ligand 1 (PD-L1) with or without lactate dehydrogenase (LDH). Previously reported cut-offs (NLR >3 and NLR >5; SII >1375) in addition to study-defined ones derived from receiver operating characteristic (ROC) analysis were used.RESULTS: The cut-off values for NLR and SII by the ROC analysis were 3.65 (sensitivity 60.4; specificity 63.0) and 884 (sensitivity 64.4; specificity 67.5), respectively. The median overall survival (OS) was 14.7 months for NLR

U2 - 10.1016/j.esmoop.2021.100118

DO - 10.1016/j.esmoop.2021.100118

M3 - Article

SN - 2059-7029

VL - 6

SP - 1

EP - 9

JO - ESMO open

JF - ESMO open

IS - 3

M1 - 100118

ER -

Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort

Abstract

Access to Document

Fingerprint

Cite this